This focused issue on “Ethnic Difference in Lung Cancer” is edited by Dr. Tomoya Kawaguchi, from Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan; and Dr. Phillip C. Mack, from University of California Davis Comprehensive Cancer Center, USA.
Dr. Tomoya Kawaguchi graduated Osaka City University and received his medical degree from the School of Medicine at 1988. He became Associate Professor, Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University at 2014, and has been Director, Chemotherapy Center, Osaka City University Hospital since 2014. He has been Chair and Professor, Department of Respiratory Medicine, Department of Medical Oncology, Graduate School of Medicine, Osaka City University since 2018. Dr. Kawaguchi’s research focuses on diagnosis and treatment in lung cancer.
Dr. Phillip C. Mack conducts molecular biology and molecular pharmacology studies for the UC Davis Cancer Center, the California Cancer Consortium, and the Southwest Oncology Group. For the past twelve years, Dr. Mack has conducted basic and translational research, with an emphasis on lung cancer. His investigations include molecular and cellular effects of novel anticancer agents in lung cancer models.
Focused issue outline:
- Different molecular profile in lung cancer: Asian vs. Caucasian
Motohiro Izumi, Osaka City University, Japan
- Different treatment efficacies and side effects of cytotoxic chemotherapy
Ross Soo, National University Institute, Singapore
- Different molecular profile in lung cancer: Japanese vs. Chinese
Wenhua Liang, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Different treatment efficacies and side effects of immunocheck inhibitors
Myung-Ju Ahn, Samsung Medical Center Sungkyunkwan Universtiy, Korea
- Difference of environment behind research and clinical practice between USA and China
Linlang Guo, Zhujiang Hospital Southern Medical University, China
- Difference of environment behind research and clinical practice between USA and Japan
Takefumi Komiya, Parkview Cancer Institute, IN, USA
- Difference of ethnicity from the clinical trials (Pooled analysis of CHEMO vs Erlotinib for EGFR WT)
Vanesa Gregorc, Scientific Institute Ospedale San Raffaele, University Hospital Milan, Italy